> Due to antagonism observed in vitro, concomitant use of remdesivir with CHLOROQUINE phosphate or HYDROXYCHLOROQUINE sulphate is not recommended. 
> Effects of remdesivir on other medicinal products In vitro , remdesivir is an inhibitor of CYP3A4, UGT1A1, MATE1, OAT3, OCT1 , OATP1B1 and OATP1B3.  Until respective clinical data become available, the coadministration of sensitive substrates of these ENZYMES and/or transporters should be considered with caution. Remdesivir induced CYP1A2 and potentially CYP3A in vitro.  Co-administration of remdesivir with CYP1A2 or CYP3A4 substrates with narrow therapeutic index may lead to loss of their efficacy. 
